Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Richmond, IN
NPI: 1366581209Primary Practice Location
REID HEALTH
1100 Reid Pkwy, Richmond, IN
Primary Employer
Reid Health Physician Associates
reidhealth.org
HQ Phone
Get D.O. Michael's Phone Numberphone_androidMobile
Get D.O. Michael's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIN State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 241 | 403 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 113 | 464 |
| 3 | 99204New patient office or other outpatient visit, 45-59 minutes | 47 | 47 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 20 | 20 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 13 | 13 |
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
Authors: Karen Reckamp, Wael Harb, Salma Jabbour, Shadia Jalal, Goetz Kloecker, Ryan Gentzler, Radhika Walling, Ebenezer Kio, Bamidele Adesunloye, Ahad Sadiq
Publication Date: 2020-10
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.
Authors: Shirish Gadgeel, Vincent Miller
Publication Date: 2017-06-15
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Docetaxel, OTHER: Laboratory Biomarker Analysis, DRUG: Trametinib
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, DRUG: Exemestane, DRUG: Entinostat, OTHER: Placebo Administration, PROCEDURE: Computed Tomography, DRUG: Goserelin Acetate, DRUG: Goserelin
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, DRUG: Lenalidomide, DRUG: Cyclophosphamide, DRUG: Prednisone, DRUG: Vincristine Sulfate, BIOLOGICAL: Rituximab, DRUG: Doxorubicin Hydrochloride
